FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116795013> ?p ?o ?g. }

• W2116795013 endingPage "583" @default.
• W2116795013 startingPage "583" @default.
• W2116795013 abstract "Selective serotonin reuptake inhibitors are widely prescribed for children with autism spectrum disorders.To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders.National Institutes of Health-sponsored randomized controlled trial.Six academic centers, including Mount Sinai School of Medicine, North Shore-Long Island Jewish Health System, University of North Carolina at Chapel Hill, University of California at Los Angeles, Yale University, and Dartmouth Medical School.One hundred forty-nine volunteers 5 to 17 years old (mean [SD] age, 9.4 [3.1] years) were randomized to receive citalopram (n = 73) or placebo (n = 76). Participants had autistic spectrum disorders, Asperger disorder, or pervasive developmental disorder, not otherwise specified; had illness severity ratings of at least moderate on the Clinical Global Impressions, Severity of Illness Scale; and scored at least moderate on compulsive behaviors measured with the Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders.Twelve weeks of citalopram hydrobromide (10 mg/5 mL) or placebo. The mean (SD) maximum dosage of citalopram hydrobromide was 16.5 (6.5) mg/d by mouth (maximum, 20 mg/d).Positive response was defined by a score of much improved or very much improved on the Clinical Global Impressions, Improvement subscale. An important secondary outcome was the score on the Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders. Adverse events were systematically elicited using the Safety Monitoring Uniform Report Form.There was no significant difference in the rate of positive response on the Clinical Global Impressions, Improvement subscale between the citalopram-treated group (32.9%) and the placebo group (34.2%) (relative risk, 0.96; 95% confidence interval, 0.61-1.51; P > .99). There was no difference in score reduction on the Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders from baseline (mean [SD], -2.0 [3.4] points for the citalopram-treated group and -1.9 [2.5] points for the placebo group; P = .81). Citalopram use was significantly more likely to be associated with adverse events, particularly increased energy level, impulsiveness, decreased concentration, hyperactivity, stereotypy, diarrhea, insomnia, and dry skin or pruritus.Results of this trial do not support the use of citalopram for the treatment of repetitive behavior in children and adolescents with autism spectrum disorders. Trial Registration clinicaltrials.gov Identifier: NCT00086645." @default.
• W2116795013 created "2016-06-24" @default.
• W2116795013 creator A5011012659 @default.
• W2116795013 creator A5011602413 @default.
• W2116795013 creator A5031278914 @default.
• W2116795013 creator A5032580621 @default.
• W2116795013 creator A5042209669 @default.
• W2116795013 creator A5044457835 @default.
• W2116795013 creator A5060810052 @default.
• W2116795013 creator A5061968864 @default.
• W2116795013 creator A5064724676 @default.
• W2116795013 creator A5070701542 @default.
• W2116795013 creator A5072643268 @default.
• W2116795013 creator A5084419495 @default.
• W2116795013 creator A5085745420 @default.
• W2116795013 date "2009-06-01" @default.
• W2116795013 modified "2023-10-02" @default.
• W2116795013 title "Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior" @default.
• W2116795013 cites W1486504114 @default.
• W2116795013 cites W1561051627 @default.
• W2116795013 cites W1706898646 @default.
• W2116795013 cites W1968430210 @default.
• W2116795013 cites W1974208535 @default.
• W2116795013 cites W1975228824 @default.
• W2116795013 cites W1976016810 @default.
• W2116795013 cites W1978189785 @default.
• W2116795013 cites W1980023413 @default.
• W2116795013 cites W1980309199 @default.
• W2116795013 cites W1980825934 @default.
• W2116795013 cites W1984567184 @default.
• W2116795013 cites W1988747626 @default.
• W2116795013 cites W1993067969 @default.
• W2116795013 cites W2000757610 @default.
• W2116795013 cites W2007181809 @default.
• W2116795013 cites W2007445647 @default.
• W2116795013 cites W2008863502 @default.
• W2116795013 cites W2018479094 @default.
• W2116795013 cites W2033946446 @default.
• W2116795013 cites W2039303946 @default.
• W2116795013 cites W2044657642 @default.
• W2116795013 cites W2045356687 @default.
• W2116795013 cites W2051143476 @default.
• W2116795013 cites W2051713615 @default.
• W2116795013 cites W2059303453 @default.
• W2116795013 cites W2063412334 @default.
• W2116795013 cites W2069963174 @default.
• W2116795013 cites W2079773266 @default.
• W2116795013 cites W2083022671 @default.
• W2116795013 cites W2092691320 @default.
• W2116795013 cites W2106291713 @default.
• W2116795013 cites W2122787629 @default.
• W2116795013 cites W2126504574 @default.
• W2116795013 cites W2128866770 @default.
• W2116795013 cites W2145914632 @default.
• W2116795013 cites W2147341063 @default.
• W2116795013 cites W2158210077 @default.
• W2116795013 cites W2159011576 @default.
• W2116795013 cites W2160214171 @default.
• W2116795013 cites W2602801922 @default.
• W2116795013 cites W3090293687 @default.
• W2116795013 doi "https://doi.org/10.1001/archgenpsychiatry.2009.30" @default.
• W2116795013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4112556" @default.
• W2116795013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19487623" @default.
• W2116795013 hasPublicationYear "2009" @default.
• W2116795013 type Work @default.
• W2116795013 sameAs 2116795013 @default.
• W2116795013 citedByCount "403" @default.
• W2116795013 countsByYear W21167950132012 @default.
• W2116795013 countsByYear W21167950132013 @default.
• W2116795013 countsByYear W21167950132014 @default.
• W2116795013 countsByYear W21167950132015 @default.
• W2116795013 countsByYear W21167950132016 @default.
• W2116795013 countsByYear W21167950132017 @default.
• W2116795013 countsByYear W21167950132018 @default.
• W2116795013 countsByYear W21167950132019 @default.
• W2116795013 countsByYear W21167950132020 @default.
• W2116795013 countsByYear W21167950132021 @default.
• W2116795013 countsByYear W21167950132022 @default.
• W2116795013 countsByYear W21167950132023 @default.
• W2116795013 crossrefType "journal-article" @default.
• W2116795013 hasAuthorship W2116795013A5011012659 @default.
• W2116795013 hasAuthorship W2116795013A5011602413 @default.
• W2116795013 hasAuthorship W2116795013A5031278914 @default.
• W2116795013 hasAuthorship W2116795013A5032580621 @default.
• W2116795013 hasAuthorship W2116795013A5042209669 @default.
• W2116795013 hasAuthorship W2116795013A5044457835 @default.
• W2116795013 hasAuthorship W2116795013A5060810052 @default.
• W2116795013 hasAuthorship W2116795013A5061968864 @default.
• W2116795013 hasAuthorship W2116795013A5064724676 @default.
• W2116795013 hasAuthorship W2116795013A5070701542 @default.
• W2116795013 hasAuthorship W2116795013A5072643268 @default.
• W2116795013 hasAuthorship W2116795013A5084419495 @default.
• W2116795013 hasAuthorship W2116795013A5085745420 @default.
• W2116795013 hasBestOaLocation W21167950132 @default.
• W2116795013 hasConcept C118552586 @default.
• W2116795013 hasConcept C126322002 @default.
• W2116795013 hasConcept C142724271 @default.
• W2116795013 hasConcept C15744967 @default.

• next